Developer docs
API playgroundTry for free, no card

Search company profiles

Coripharma

Full company profile

uuid0029fys

Namestring
Coripharma
Legal namestring
Coripharma
Websiteurl
coripharma.is
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Coripharma is a privately held European generic pharmaceutical company headquartered in Hafnarfjörður, Iceland. Founded in 2018 through the acquisition of Icelandic manufacturing assets and vertically integrated in 2019 with the acquisition of on-site R&D operations, Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) at a GMP-approved facility that is operated entirely on renewable geothermal and hydropower energy. By 2025, the portfolio comprises 39 products spanning oncology (Binimetinib, Ponatinib), antiviral therapy (Letermovir), cystic fibrosis (Ivacaftor), ADHD (Lisdexamphetamine) and inflammation (Apremilast), with 16 dossiers completed from its own development since inception.

The commercial model is B2B out-licensing into Europe. Coripharma produces the complete dossier, conducts regulatory submissions, and supplies finished product to over 50 European pharmaceutical partners who commercialize under their own brand names in their respective markets. The dedicated business development team pursues additional out-licensing agreements and manages partner relationships; the offering includes patent landscape analysis, artwork design and reliable GMP manufacturing supply. Day-1 at patent expiry is treated as a core competency, demonstrated by the 17 January 2026 launch of Apremilast in Germany through a local partner immediately following patent expiry, including the production of a multi-strength blister starter pack at the Icelandic site.

Coripharma is led by CEO Jónína Guðmundsdóttir (joined 2020; 20+ years pharma experience, formerly VP at Medis) with a CFO hire from Hansa Biopharma in 2023 and a recently expanded engineering, quality, supply chain, R&D, HR and business development leadership team. The company holds ÍST 85:2012 equal pay certification, an Excellent Workplace Certificate, and an ISO-certified hosting arrangement, and publishes annual sustainability reports; ownership, investors and audited financials are not publicly disclosed.

Short descriptiontext

Coripharma is an Iceland-based, privately held European generic pharmaceutical company that develops and manufactures technically challenging oral solid dose generics and out-licenses dossiers and supply to over 50 European pharmaceutical partners across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHafnarfjörður, Iceland
HQ citystring
Hafnarfjörður
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, out-licensing partnerships, oral solid dose manufacturing, generic drug development, regulatory dossier services
Industry2 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Out-licensing
TypeLicensing Royalties
Description

Coripharma develops generic pharmaceutical dossiers and out-licenses them to European partners who commercialize products under their own brand. The company provides complete documentation, regulatory support, and manufactured product supply.

coripharma.is
2Contract Manufacturing
TypeHardware Sales
Description

Manufacturing and supply of generic pharmaceuticals from GMP-approved Icelandic facility to out-licensing partners across Europe.

coripharma.is
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) and out-licenses the resulting dossiers, regulatory support, and finished product supply to European pharmaceutical partners who commercialize the medicines under their own brand. Operations are performed in-house at a GMP-approved, renewable-energy-powered facility in Hafnarfjörður, Iceland, covering the full development cycle from formulation and bioequivalence studies through to regulatory submissions and commercial supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Day-1 patent launch achieved for Apremilast in Germany
+2 more records
Product overview1 text field

Coripharma is a European generic pharmaceutical company offering an integrated product development and manufacturing platform. The core offering includes Development to Market services (developing technically challenging generic oral solid dose pharmaceuticals) combined with Out-licensing partnerships for European pharmaceutical companies. The company operates a GMP-approved manufacturing facility in Iceland running on 100% renewable energy. The product portfolio spans multiple therapeutic areas including oncology (Binimetinib, Ponatinib), antiviral (Letermovir), cystic fibrosis (Ivacaftor), CNS (Lisdexamphetamine, Apremilast), with 39 products in portfolio and 8 products launched as of 2025. The company provides comprehensive regulatory support, dossier documentation, and reliable manufacturing supply to its out-licensing partners across Europe.

Product and service8 records
1Development to Market
CategoryPharmaceutical development and manufacturing service
Description

End-to-end development and manufacturing service for technically challenging generic oral solid dose pharmaceuticals (tablets, capsules), targeting high-value, low-volume products where development complexity creates competitive opportunity. Delivered from Coripharma's GMP-approved Icelandic facility with integrated R&D and manufacturing for European out-licensing partners.

2Out-licensing to European Partners
CategoryPharmaceutical out-licensing partnership
Description

B2B out-licensing of Coripharma-developed generic pharmaceutical dossiers to European pharmaceutical partners, including complete regulatory documentation, patent landscape analysis, artwork design, and commercial product supply from the GMP-approved Icelandic facility. Partners commercialize the products under their own brand in their home markets.

3Binimetinib Tablets (generic)
CategoryGeneric oncology product (MEK inhibitor)
Description

Generic oral MEK inhibitor tablet for melanoma treatment (in combination with encorafenib) bioequivalent to the reference product Mektovi. Part of Coripharma's oncology portfolio and offered through out-licensing to European partners.

4Letermovir Tablets (generic)
CategoryGeneric antiviral product
Description

Generic oral antiviral tablet for prophylaxis of cytomegalovirus reactivation. Part of Coripharma's antiviral portfolio and offered through out-licensing to European partners.

5Ponatinib (generic)
CategoryGeneric oncology product
Description

Generic oncology product used in treatment of certain forms of leukemia, based on reference product Iclusig. Offered through out-licensing to European partners.

6Ivacaftor Tablets (generic)
CategoryGeneric cystic fibrosis product (CFTR potentiator)
Description

Generic CFTR potentiator tablets for cystic fibrosis treatment, available in 75mg and 150mg strengths, offered through out-licensing to European partners.

7Apremilast (generic)
CategoryGeneric dermatology/rheumatology product
Description

Generic Apremilast launched in Germany on Day-1 of patent expiry with a first-of-its-kind multi-strength starter pack blister presentation. Launched in collaboration with a German partner and supported across additional European countries.

8Lisdexamphetamine (generic)
CategoryGeneric CNS product (ADHD)
Description

Generic CNS product for ADHD management based on reference product Elvanse; the 16th dossier completed from Coripharma's own development and offered through out-licensing to European partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1German Partner (Apremilast)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-17
Description

Close collaboration with German pharmaceutical partner for successful Day-1 patent launch of Apremilast in Germany. Coripharma also supported rollout in other countries, adding further presence within the European market. This represents an important milestone in Coripharma's European commercial activities.

coripharma.is
Strategic tierSupportingTypeTechnology or Integration
Description

Partnership with Klappir, a smart sustainability platform, for measuring and reducing carbon footprint across all business activities. Through this partnership, Coripharma tracks environmental metrics and works toward sustainability goals.

3European Pharmaceutical Partners (50+ companies)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Coripharma has signed with over 50 pharmaceutical companies including major European players for out-licensing partnerships. These partners receive dossiers, regulatory support, and manufactured products for commercialization across European markets.

coripharma.is
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Slovenian-headquartered European generic manufacturer with vertically integrated development and manufacturing and growing presence in technically demanding generics. Comparable end-market and partner model, though at substantially larger scale.

TypeBroad incumbent
Description

European generics leader with integrated development, dossier, and manufacturing capabilities across multiple dosage forms. Comparable strategy of targeting Central and broader European markets with out-licensing and supply partnerships.

3Sandoz
TypeBroad incumbent
Description

Global generic and biosimilar leader spun out of Novartis, with deep European dossier development and manufacturing scale. Relevant overlap with Coripharma across European out-licensing partnerships and complex generic selection.

TypeBroad incumbent
Description

Large European generic and specialty pharma incumbent with a broad generic portfolio and significant out-licensing activity. Overlaps with Coripharma in technically challenging generics and European out-licensing channels, but at much greater scale and breadth.

TypeBroad incumbent
Description

World's largest generic manufacturer with substantial European dossier and out-licensing footprint. Increasingly competing for technically challenging generics where Coripharma currently differentiates.

TypeBroad incumbent
Description

Canadian-headquartered generic manufacturer with established European presence and dossier/supply operations. Comparable focus on out-licensing dossiers and finished-dose supply to regional partners.

TypeDirect peer
Description

European-focused specialty generic pharmaceutical company with a similar out-licensing and dossier-supply model in technically challenging generics. Direct comparability: Coripharma's CEO and several directors (Commercial Operations, Supply Chain) were previously senior leaders at Medis, indicating closely matched operating playbooks.

TypeDirect peer
Description

Out-licensing and specialty generic player with strong European footprint and operations touching Iceland. Coripharma's CFO Ludvik Karl Tomasson was previously at Alvogen, underscoring operational overlap in dossier development, partner commercial models, and complex-generics strategy.

TypeRegional player
Description

Hungary-based European generic pharmaceutical company with integrated R&D and manufacturing, focused on Central and Eastern European markets with growing Western European out-licensing activity. Comparable vertical integration and specialty-generics portfolio strategy.

TypeBroad incumbent
Description

Indian-headquartered global generic manufacturer expanding aggressively in European complex generics, including oncology and CNS — the same therapeutic categories Coripharma is targeting. Represents the most active price-competition threat.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coripharma

Generic Pharmaceuticalscoripharma.is

Coripharma is an Iceland-based, privately held European generic pharmaceutical company that develops and manufactures technically challenging oral solid dose generics and out-licenses dossiers and supply to over 50 European pharmaceutical partners across Europe.

What Coripharma does

Coripharma is a privately held European generic pharmaceutical company headquartered in Hafnarfjörður, Iceland. Founded in 2018 through the acquisition of Icelandic manufacturing assets and vertically integrated in 2019 with the acquisition of on-site R&D operations, Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) at a GMP-approved facility that is operated entirely on renewable geothermal and hydropower energy. By 2025, the portfolio comprises 39 products spanning oncology (Binimetinib, Ponatinib), antiviral therapy (Letermovir), cystic fibrosis (Ivacaftor), ADHD (Lisdexamphetamine) and inflammation (Apremilast), with 16 dossiers completed from its own development since inception.

The commercial model is B2B out-licensing into Europe. Coripharma produces the complete dossier, conducts regulatory submissions, and supplies finished product to over 50 European pharmaceutical partners who commercialize under their own brand names in their respective markets. The dedicated business development team pursues additional out-licensing agreements and manages partner relationships; the offering includes patent landscape analysis, artwork design and reliable GMP manufacturing supply. Day-1 at patent expiry is treated as a core competency, demonstrated by the 17 January 2026 launch of Apremilast in Germany through a local partner immediately following patent expiry, including the production of a multi-strength blister starter pack at the Icelandic site.

Coripharma is led by CEO Jónína Guðmundsdóttir (joined 2020; 20+ years pharma experience, formerly VP at Medis) with a CFO hire from Hansa Biopharma in 2023 and a recently expanded engineering, quality, supply chain, R&D, HR and business development leadership team. The company holds ÍST 85:2012 equal pay certification, an Excellent Workplace Certificate, and an ISO-certified hosting arrangement, and publishes annual sustainability reports; ownership, investors and audited financials are not publicly disclosed.

Coripharma firmographics

Firmographics
Name
Coripharma
Legal name
Coripharma
Website
https://coripharma.is
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Coripharma is an Iceland-based, privately held European generic pharmaceutical company that develops and manufactures technically challenging oral solid dose generics and out-licenses dossiers and supply to over 50 European pharmaceutical partners across Europe.
Ownership category
akta.pro rank

Coripharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Generic pharmaceuticals
  • Out-licensing partnerships
  • Oral solid dose manufacturing
  • Generic drug development
  • Regulatory dossier services

Where Coripharma is headquartered

Location

Headquarters

HQ city
Hafnarfjörður
HQ country
Iceland
HQ region
Europe

Offices1 record

Markets served

Coripharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Product Out-licensing: Coripharma develops generic pharmaceutical dossiers and out-licenses them to European partners who commercialize products under their own brand. The company provides complete documentation, regulatory support, and manufactured product supply.
  2. Contract Manufacturing: Manufacturing and supply of generic pharmaceuticals from GMP-approved Icelandic facility to out-licensing partners across Europe.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Coripharma product offering

Product offering

Core offering

Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) and out-licenses the resulting dossiers, regulatory support, and finished product supply to European pharmaceutical partners who commercialize the medicines under their own brand. Operations are performed in-house at a GMP-approved, renewable-energy-powered facility in Hafnarfjörður, Iceland, covering the full development cycle from formulation and bioequivalence studies through to regulatory submissions and commercial supply.

Product overview

Coripharma is a European generic pharmaceutical company offering an integrated product development and manufacturing platform. The core offering includes Development to Market services (developing technically challenging generic oral solid dose pharmaceuticals) combined with Out-licensing partnerships for European pharmaceutical companies. The company operates a GMP-approved manufacturing facility in Iceland running on 100% renewable energy. The product portfolio spans multiple therapeutic areas including oncology (Binimetinib, Ponatinib), antiviral (Letermovir), cystic fibrosis (Ivacaftor), CNS (Lisdexamphetamine, Apremilast), with 39 products in portfolio and 8 products launched as of 2025. The company provides comprehensive regulatory support, dossier documentation, and reliable manufacturing supply to its out-licensing partners across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

  • Development to Market End-to-end development and manufacturing service for technically challenging generic oral solid dose pharmaceuticals (tablets, capsules), targeting high-value, low-volume products where development complexity creates competitive opportunity. Delivered from Coripharma's GMP-approved Icelandic facility with integrated R&D and manufacturing for European out-licensing partners.
  • Out-licensing to European Partners B2B out-licensing of Coripharma-developed generic pharmaceutical dossiers to European pharmaceutical partners, including complete regulatory documentation, patent landscape analysis, artwork design, and commercial product supply from the GMP-approved Icelandic facility. Partners commercialize the products under their own brand in their home markets.
  • Binimetinib Tablets (generic) Generic oral MEK inhibitor tablet for melanoma treatment (in combination with encorafenib) bioequivalent to the reference product Mektovi. Part of Coripharma's oncology portfolio and offered through out-licensing to European partners.
  • Letermovir Tablets (generic) Generic oral antiviral tablet for prophylaxis of cytomegalovirus reactivation. Part of Coripharma's antiviral portfolio and offered through out-licensing to European partners.
  • Ponatinib (generic) Generic oncology product used in treatment of certain forms of leukemia, based on reference product Iclusig. Offered through out-licensing to European partners.
  • Ivacaftor Tablets (generic) Generic CFTR potentiator tablets for cystic fibrosis treatment, available in 75mg and 150mg strengths, offered through out-licensing to European partners.
  • Apremilast (generic) Generic Apremilast launched in Germany on Day-1 of patent expiry with a first-of-its-kind multi-strength starter pack blister presentation. Launched in collaboration with a German partner and supported across additional European countries.
  • Lisdexamphetamine (generic) Generic CNS product for ADHD management based on reference product Elvanse; the 16th dossier completed from Coripharma's own development and offered through out-licensing to European partners.

Quantifiable outcome

  • Day-1 patent launch achieved for Apremilast in Germany
  • +2 more outcomes

Companies that use Coripharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Coripharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Coripharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • German Partner (Apremilast)coreStrategic or Co-development Partner · 17 January 2026Close collaboration with German pharmaceutical partner for successful Day-1 patent launch of Apremilast in Germany. Coripharma also supported rollout in other countries, adding further presence within the European market. This represents an important milestone in Coripharma's European commercial activities.
  • KlappirsupportingTechnology or IntegrationPartnership with Klappir, a smart sustainability platform, for measuring and reducing carbon footprint across all business activities. Through this partnership, Coripharma tracks environmental metrics and works toward sustainability goals.
  • European Pharmaceutical Partners (50+ companies)coreChannel Partner/ Reseller/ DistributorCoripharma has signed with over 50 pharmaceutical companies including major European players for out-licensing partnerships. These partners receive dossiers, regulatory support, and manufactured products for commercialization across European markets.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Coripharma competitors and assessment

Company assessment

Broad incumbents

  • Krka: Slovenian-headquartered European generic manufacturer with vertically integrated development and manufacturing and growing presence in technically demanding generics. Comparable end-market and partner model, though at substantially larger scale.
  • Polpharma: European generics leader with integrated development, dossier, and manufacturing capabilities across multiple dosage forms. Comparable strategy of targeting Central and broader European markets with out-licensing and supply partnerships.
  • Sandoz: Global generic and biosimilar leader spun out of Novartis, with deep European dossier development and manufacturing scale. Relevant overlap with Coripharma across European out-licensing partnerships and complex generic selection.
  • Stada Arzneimittel: Large European generic and specialty pharma incumbent with a broad generic portfolio and significant out-licensing activity. Overlaps with Coripharma in technically challenging generics and European out-licensing channels, but at much greater scale and breadth.
  • Teva Pharmaceutical Industries: World's largest generic manufacturer with substantial European dossier and out-licensing footprint. Increasingly competing for technically challenging generics where Coripharma currently differentiates.
  • Apotex: Canadian-headquartered generic manufacturer with established European presence and dossier/supply operations. Comparable focus on out-licensing dossiers and finished-dose supply to regional partners.
  • Aurobindo Pharma: Indian-headquartered global generic manufacturer expanding aggressively in European complex generics, including oncology and CNS — the same therapeutic categories Coripharma is targeting. Represents the most active price-competition threat.

Direct peers

  • Medis: European-focused specialty generic pharmaceutical company with a similar out-licensing and dossier-supply model in technically challenging generics. Direct comparability: Coripharma's CEO and several directors (Commercial Operations, Supply Chain) were previously senior leaders at Medis, indicating closely matched operating playbooks.
  • Alvogen: Out-licensing and specialty generic player with strong European footprint and operations touching Iceland. Coripharma's CFO Ludvik Karl Tomasson was previously at Alvogen, underscoring operational overlap in dossier development, partner commercial models, and complex-generics strategy.

Regional players

  • Gedeon Richter: Hungary-based European generic pharmaceutical company with integrated R&D and manufacturing, focused on Central and Eastern European markets with growing Western European out-licensing activity. Comparable vertical integration and specialty-generics portfolio strategy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Coripharma social profiles

Digital presence

Coripharma compliance and trust

Trust signal

Compliance4 records

Coripharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coripharma leadership team

Management profile

Number of profiles

Profiles9 records

Coripharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coripharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coripharma

What does Coripharma do?

Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) and out-licenses the resulting dossiers, regulatory support, and finished product supply to European pharmaceutical partners who commercialize the medicines under their own brand. Operations are performed in-house at a GMP-approved, renewable-energy-powered facility in Hafnarfjörður, Iceland, covering the full development cycle from formulation and bioequivalence studies through to regulatory submissions and commercial supply.

Is Coripharma a public or private company?

Coripharma is a private company. It is classified as unknown and is currently operating.

When was Coripharma founded?

Coripharma was founded in 2018. It employs 101 to 250 people.

Where is Coripharma based?

Coripharma is headquartered in Hafnarfjörður, Iceland, in the Europe region.

How does Coripharma make money?

Two revenue lines are on record. Product Out-licensing is the primary driver. The others are contract Manufacturing.

Who are Coripharma's main competitors?

Broad incumbents on record are Krka, Polpharma, Sandoz, Stada Arzneimittel, Teva Pharmaceutical Industries, Apotex and Aurobindo Pharma. Direct peers are Medis and Alvogen. Gedeon Richter is listed as a regional player.

Does Coripharma have an API?

No public API is recorded for Coripharma.

What industry is Coripharma in?

Coripharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales